Stephen Burnside

Dr. Stephen Burnside

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
AMAdam McArthur
Adam McArthur
SWStephanie Wichuk
Stephanie Wichuk
SBStephen Burnside
Stephen Burnside
GRGeorge Reed
George Reed
SDSukhdeep Kaur Dulai
Sukhdeep Kaur Dulai
JJJacob Lester Jaremko
Jacob Lester Jaremko
This study evaluates Retuve, an open-source explainable pipeline for the automated analysis of infant hip ultrasound cine sweeps. Retuve combines segmentation, Graf-plane calibration, and frame filtering. In a retrospective multicenter study, we tested the full pipeline on an external set of 109 hips from a Canadian community clinic, with internal developmental validation of segmentation on 90 hips and Graf-plane calibration on 419 hips. On the external test set, Retuve achieved 100% specificity and 91% sensitivity for expert agreement regarding whether a sweep contained an analyzable frame, compared with 75% specificity and 96% sensitivity for a radiology fellow; specificity was based on 16 expert-negative examinations. For alpha angle and acetabular coverage, Retuve achieved consistency intraclass correlation coefficients (ICCs) of 0.77 and 0.74, comparable to the fellow’s 0.70 and 0.74. However, alpha-angle absolute agreement was lower (ICC 0.55, 95% confidence interval (CI) −0.07–0.81), consistent with systematic measurement bias. Internal developmental validation showed Component 1 mask mean average precision at 50% intersection-over-union (mAP50) of 0.753 and box mAP50 of 0.883 and a Component 2 ICC of 0.792. Retuve can select analyzable frames and recover measurements from variable-quality cine sweeps, but alpha-angle calibration requires refinement. Future prospective work should evaluate developmental dysplasia of the hip (DDH) diagnostic accuracy, clinical treatment decision support, and screening outcomes.